alliances, the impact
of competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time to time in the Company's ongoing quarterly and annual reporting.
Financials results included below:
Bradmer Pharmaceuticals Inc.
Balance Sheets
US $
December 31, December 31,
2007 2006
------------- -------------
Assets
Current
Cash $ 19,469,337 $ 8,813,427
Amounts receivable 143,722 77,085
Prepaid expenses and other assets 24,029 10,632
------------- -------------
19,637,088 8,901,144
Patent rights 685,165 469,817
------------- -------------
$ 20,322,253 $ 9,370,961
------------- -------------
------------- -------------
Liabilities
Current
Accounts payable and accrued liabilities $ 1,835,492 $ 1,384,367
------------- -------------
Shareholders' Equity
Capital stock 31,026,728 12,504,066
Contributed surplus 714,981 183,369
Warrants 881,488 -
Deficit (14,136,436) (4,700,841)
'/>"/>
SOURCE Bradmer Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related medicine news :1.
Notice of Bradmer Pharmaceuticals Conference Call2.
Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study3.
Bradmer to present at the 10th Annual BIO CEO & Investor Conference4.
Bradmer announces additions to Scientific Advisory Board5.
Bradmer Medical Isotope Supply For Phase III Trial Secure6.
Bradmer to present at Rodman & Renshaw Healthcare Conference7.
Bradmer provides Phase III Neuradiab trial update and guidance8.
Bradmer announces management changes9.
NHP Announces Management Promotions10.
WellPoint Announces Appearances at Upcoming Conferences11.
Mettler-Toledo International Inc. Announces Webcast of Presentation at Lehman Brothers Global Healthcare Conference